

## Company Overview

CEL-SCI is a Phase 3 cancer immunotherapy company. When it comes to cancer immunotherapy, CEL-SCI believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival. Therefore, CEL-SCI treats patients who are newly diagnosed with cancer with its lead investigational immunotherapy Multikine\* right after diagnosis, **before** they have received surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are used only after conventional therapies have been tried or failed. CEL-SCI finished enrolling 928 patients in its pivotal Phase 3 head and neck cancer study in September 2016. These treated patients are now being monitored for overall survival. Head and neck cancer is a multi-billion dollar global market representing about 6% of all cancers and an unmet medical need. Multikine has received Orphan Drug designation from the FDA for this indication. CEL-SCI is also developing a novel vaccine for the treatment of rheumatoid arthritis using its investigational platform technology LEAPS and received a \$1.5 M grant from the NIH.

### RECENT & UPCOMING CATALYSTS

- ❖ **Management bought shares recently**
  - In August 2018 the CEO purchased 300,000 shares
  - In August 2018 other senior managers purchased 162,000 shares
- ❖ **Phase 3 Study Results**
  - CEL-SCI is nearing reporting Phase 3 results
  - Primary end-point is 10% improvement in overall survival; CEL-SCI's prior Phase 2 study had shown a 33% increase in overall survival
  - If the results are positive, CEL-SCI intends to file for marketing approval worldwide

### HEAD & NECK CANCER MARKET

- ❖ 6% of all cancers are head & neck
- ❖ 650,000 new cases each year globally with 60,000 in the U.S. and 105,000 in Europe
- ❖ 300,000 deaths per year
- ❖ FDA has not approved a new drug for treatment of advanced primary head and neck cancer in over 60 years

*Disclaimer:*

Except for historical information contained herein, the statements in this fact sheet are "forward looking" within the meaning of the Private Securities Litigation Act of 1995. A fuller discussion of CEL-SCI Corporation's risks and uncertainties are described in the Company's filings with the Securities and Exchange Commission, which should be reviewed in conjunction with this overview.

*\*Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase 3 clinical trial of this investigational therapy that is currently in progress.*

### Investment Highlights


#### Multikine Modulates/Mobilizes Intact Immune Response to Kill Cancer

Treating newly diagnosed cancer patients with an immunotherapy before surgery, radiation and chemotherapy should reduce recurrence and improve overall survival. The goal is to help the intact immune response detect and kill the tumor and micro metastases that usually cause recurrence of cancer. Therefore, Multikine is given right after diagnosis, before any other treatment. Other Phase 3 cancer immunotherapy studies are conducted in terminal cancer patients who have already failed standard therapies. Multikine is designed to allow a person's own intact immune system cells to attack their own cancer.

#### Phase 3 Trial's Positive Results Could Lead to Approval

In CEL-SCI's pivotal Phase 3 clinical trial, Multikine is given as a first line treatment before surgery, radiation or concurrent radio-chemotherapy because that is when the immune system is thought to be the strongest. The last patient enrolled in the study in September 2016. At present, 928 patients have been enrolled and are now being followed for overall survival. The primary endpoint of the study is a 10% improvement in overall survival for patients treated with Multikine plus Standard of Care (SOC) vs. patients treated with SOC alone. A prior Phase 2 study using the same treatment regimen showed a 33% increase in overall survival, as compared to patient survival reported in the scientific literature between 1987 and 2007. The determination if the Phase 3 Study primary end point has been met will occur when there are a total of 298 deaths in the two main groups.

#### Multikine Treatment Regimen Schematic:



#### LEAPS Therapeutic Vaccines for Treatment of Rheumatoid Arthritis

LEAPS is CEL-SCI's second proprietary technology platform. It is a new class of drug that acts early to treat autoimmune and infectious diseases. Research has been funded via collaborations with the U.S. National Institutes of Health (NIH), U.S. Army, Navy, and universities. The first indication is rheumatoid arthritis currently being funded by a \$1.5 M grant from the NIH.

#### Robust IP Portfolio and Full-Scale Manufacturing Facility

CEL-SCI operates its own 73,000 sq. ft. manufacturing facility and produces Multikine for its clinical trials. About \$100 M was spent on the manufacturing plant, development, and validation. CEL-SCI believes Multikine is very difficult to replicate. In addition to the many Multikine manufacturing trade secrets, CEL-SCI has received a number of patents for Multikine from the U.S., EU, China and Japan.